Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan (Sac-TMT) Alone or in Combination in mCRPC/APMR
NCT07908524Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2026
- Primary completion
- Jun 2032
01
Overview
Phase 2, randomised, open-label trial of sacituzumab tirumotecan in metastatic castration-resistant prostate cancer (mCRPC) (5 arms), sponsored by Merck & Co. Primary endpoints: Objective Response Rate at 66 months, Number of Participants Who Experience at Least One Adverse Event at 66 months and 2 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07908524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908524.